Recombinant Human STEAP1 Protein，His

STEAP1 (six-transmembrane epithelial antigen of prostate 1) is an integral membrane protein that has gained significant interest due to its prominent role in cancer biology, particularly in prostate cancer. As a member of the STEAP family, STEAP1 is characterized by its six transmembrane domains and is primarily expressed in prostate tissues, making it a potential biomarker for prostate cancer diagnosis and therapy. Research has revealed that STEAP1 is involved in various cellular processes, including iron metabolism and cellular differentiation, which are crucial for tumor progression. The overexpression of STEAP1 in malignant tissues compared to normal epithelial cells suggests its potential as a therapeutic target. Recombinant STEAP1 proteins have been developed for further investigation into its biological functions, interactions, and potential as a target for immunotherapy. Studies on STEAP1 recombinant proteins have focused on understanding its structure-function relationship and elucidating mechanisms of action in cancer cells. These efforts aim to pave the way for novel therapeutic strategies, including monoclonal antibodies or vaccine-based approaches that could lead to more effective treatments for prostate cancer. Additionally, the study of STEAP1 offers insights into potential pathways that could be exploited in targeting other malignancies where STEAP proteins are implicated, thus broadening the scope of applications for STEAP1-related research. Overall, the investigation of recombinant STEAP1 proteins stands at the intersection of cancer biology and therapeutic innovation, highlighting its significance in the ongoing effort to develop targeted cancer therapies.